For the year ending 2025-12-31, SHC had $67,591K increase in cash & cash equivalents over the period. $149,177K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 77,949 |
| Depreciation | 94,908 |
| Amortization of intangible assets | 41,798 |
| Loss on refinancing of debt | -1,462 |
| Deferred income taxes | 22 |
| Share-based compensation expense | 30,878 |
| Accretion expense | 2,321 |
| Unrealized foreign exchange loss (gain) | -9,517 |
| Unrealized (gain) loss on derivatives not designated as hedging instruments | 863 |
| Amortization of debt issuance costs | 5,434 |
| Other | 4,275 |
| Accounts receivable | -7,151 |
| Inventories | 2,377 |
| Other current assets | 12,902 |
| Accounts payable | 5,185 |
| Accrued liabilities | 1,941 |
| Litigation settlement-Ethylene Oxide Tort Litigation Illinois | 34,000 |
| Litigation settlement-Ethylene Oxide Tort Litigation Georgia | 0 |
| Income taxes payable / receivable, net | -5,461 |
| Other liabilities | 295 |
| Other long-term assets | -212 |
| Net cash provided by (used in) operating activities | 287,195 |
| Purchases of property, plant and equipment | 138,018 |
| Other investing activities | -2,874 |
| Net cash used in investing activities | -135,144 |
| Proceeds from long-term borrowings | 0 |
| Payment of revolving credit facility | 0 |
| Payments of debt issuance costs and debt discount | 4,374 |
| Payments of long-term borrowings | 86,104 |
| Buyout of leased facility | 0 |
| Shares withheld for employee taxes on equity awards | 6,568 |
| Other financing activities | -3,488 |
| Net cash (used in) provided by financing activities | -100,534 |
| Effect of exchange rate changes on cash and cash equivalents | 16,074 |
| Net increase (decrease) in cash and cash equivalents, including restricted cash | 67,591 |
| Cash and cash equivalents, including restricted cash, at beginning of period | 278,865 |
| Cash and cash equivalents, including restricted cash, at end of period | 346,456 |
Sotera Health Co (SHC)
Sotera Health Co (SHC)